Also trades as: GLTO (NASDAQ) · $vol 5M
DMRA NASDAQ
Damora Therapeutics, Inc.
1W: +10.3%
1M: +2.9%
3M: -27.7%
YTD: -11.1%
$21.96
+0.70 (+3.29%)
After Hours: $22.00 (+0.04, +0.18%)
Weekly Expected Move ±8.3%
$18
$19
$21
$23
$25
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history. Altman Z'' 19.30.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3B
52W Range4.95-38.33
Volume641,718
Avg Volume622,390
Beta1.44
Dividend—
Analyst Ratings
Company Info
CEOJennifer A. Jarrett
Employees7
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-29
Websitedamoratx.com
Building 23
Waltham, MA 02453
US
Waltham, MA 02453
US
457 070 5210
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The companyâs lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Latest News
Damora Therapeutics: Potential Payday Is A Long Way Off (NASDAQ:DMRA) - Seeking Alpha
Technical Reactions to DMRA Trends in Macro Strategies - Stock Traders Daily
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jarrett Jennifer | P-Purchase | 12,500 | $20.23 | 2026-09-25 |
| Cheng Andrew | A-Award | 30,350 | $31.00 | 2026-08-12 |
| Cheng Andrew | 0 | — | 2026-08-12 | |
| Winslow Garrett | S-Sale | 245 | $29.98 | 2026-07-06 |
| Winslow Garrett | M-Exempt | 680 | — | 2026-07-03 |